Evidence map›Paper›PMID 42350046›Full record

ArticleJournal for immunotherapy of cancer2026

FLT3L-secreting cDC1 in situ vaccination enhances antitumor immunity and synergizes with PD-1 blockade in murine non-small cell lung cancer.

Jensen Abascal, Camelia Dumitras, Linh M Tran, William Crosson, Bitta Kahangi, Michael Oh, Austin Rennels, Raymond J Lim, Hong Jiang, Diana Reyimjan and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Jensen AbascalDepartment of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.ORCID http://orcid.org/0000-0002-7529-1004
Camelia DumitrasDepartment of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Linh M TranDepartment of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
William CrossonDepartment of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Bitta KahangiDepartment of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.ORCID http://orcid.org/0000-0002-2726-0190
Michael OhDepartment of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Austin RennelsDepartment of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.ORCID http://orcid.org/0009-0009-0059-5677
Raymond J LimDepartment of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Hong JiangDepartment of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Diana ReyimjanDepartment of Microbiology, Immunology, and Molecular Genetics, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Nalani J ColemanDepartment of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Edgar Perez-ReyesDepartment of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Samantha ChinDepartment of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Kostyantyn KrysanDepartment of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Steven M DubinettDepartment of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Bin LiuDepartment of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA rsalehirad@mednet.ucla.edu bliu@mednet.ucla.edu.ORCID http://orcid.org/0000-0001-8083-8062
Ramin Salehi-RadDepartment of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA rsalehirad@mednet.ucla.edu bliu@mednet.ucla.edu.ORCID http://orcid.org/0000-0003-1543-5421

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Robert Damoiseaux · 1985 to 2026
$134.5M
Virology CoreP30AI028697 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ZACK, JEROME A. · 1991 to 2018
$39.9M
UCLA Tumor Immunology Training ProgramT32CA009120 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Steven M. Dubinett, MICHAEL A TEITELL · 1985 to 2026
$10.3M
BLRD VA I01 BX004717BLRD VA IK2 BX006194NCI NIH HHS P30 CA016042NCI NIH HHS T32 CA009120NIAID NIH HHS P30 AI028697
6 · The paper itself

Abstract

backgroundNon-small cell lung cancer (NSCLC) frequently evades immune surveillance through defective antigen presentation and a suppressive tumor microenvironment (TME), limiting the efficacy of immune checkpoint blockade (ICB). Conventional type 1 dendritic cells (cDC1s) are essential for initiating antitumor CD8

methodsSyngeneic murine models of NSCLC (

resultsFLT3L-cDC1 ISV remodeled the TME across multiple NSCLC models, inducing T lymphocyte infiltration and expanding cytolytic CD8

conclusionsFLT3L-cDC1 ISV represents a rational cytokine-enhanced cellular immunotherapy designed to overcome immunosuppression and restore DC function within the TME, thereby promoting tumor-specific adaptive immune responses and enhancing responsiveness to ICB.

Indexed as

Cancer VaccinesCarcinoma, Non-Small-Cell LungDendritic CellsImmune Checkpoint InhibitorsLung NeoplasmsMembrane ProteinsProgrammed Cell Death 1 ReceptorAnimalsHumansMiceTumor MicroenvironmentVaccinationCancer Vaccinesflt3 ligand proteinImmune Checkpoint InhibitorsMembrane ProteinsProgrammed Cell Death 1 ReceptorDendriticImmunotherapyLung CancerVaccine

Identifiers

PMID42350046
PMCPMC13311619

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.